Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Although sanitary landfill is one of the principal municipal solid waste (MSW) treatment and disposal methods, its limitations, such as insufficient use of resources, long stability time, and high risk of environmental pollution, must be urgently resolved. The effect of multifunctional microbial community (MMC) inoculation on MSW landfill process was investigated using simulated anaerobic bioreactor landfill (ABL), and composition and microbial community structure of waste, leachate water quality, and gas production were monitored. MMC inoculation significantly accelerated lignocellulose degradation, and the (Hemicellulose content + Cellulose content)/Lignin content ((C + H)/L) of MMC inoculation treatment was 0.89 ± 0.04 on day 44, which was significantly lower than that of the control group (1.14 ± 0.02). At the end of the landfill process, the reductive organic matter, ammonia nitrogen, and volatile fatty acids in the leachate of the MMC group decreased to 9400.00 ± 288.68, 332.78 ± 5.77, and 79.33 ± 6.44 mg L, respectively, significantly lower than those of the control group (24,167.00 ± 208.17, 551.14 ± 5.60, and 156.33 ± 8.22 mg L). Meanwhile, MMC inoculation increased the methane production to 118.12 ± 5.42 L kg of dry matter, significantly higher than the output of the control group (60.60 ± 2.24 L kg). MMC inoculation optimized the microbial community structure in ABL and increased lignocellulose-degrading microorganisms (Brevundimonas, Cellvibrio, Leifsonia, and Devosia) and methanogen (Methanosaeta and Methanoculleus) abundance in the middle stage of landfill. Moreover, MMC introduction improved the abundance of carbon metabolism enzymes and increased saprophytic fungal abundance by 30.09% in the middle stage of landfill. Overall, these findings may help in developing an effective method to increase the lifespan of landfills and enhance their post-closure management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.chemosphere.2024.142984 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adverse events associated with COVID-19 vaccination or diagnosis among pregnant and non-pregnant women in the United States, 2021-2022.
Int J Infect Dis
September 2025
University of San Francisco, Department of Nursing and Health Professions, San Francisco, California, United States; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Epidemiology, Fielding School of Public Health, University of California, Los A
Objectives: To quantify the incidence of adverse events given COVID-19 vaccination and COVID-19 diagnosis in women of reproductive age; to examine pregnancy as a potential risk modifier.
Methods: An exposure-matched cohort study of >1 million women, 11 December 2020-30 September 2022, United States. COVID-19 vaccination, COVID-19 diagnoses, and medically-attended adverse events - including immunologic, neurologic, cerebrovascular, thromboembolic, cardiovascular, respiratory, thrombocytopenic and coagulative events - were identified from inpatient and outpatient medical claims.
Indian National Association for the Study of the Liver Position Statements on Prevention, Diagnosis, and Management of Hepatitis B Virus Infection in India.
J Clin Exp Hepatol
June 2025
Department of Gastroenterology, Sree Gokulam Medical College and Research Foundation Trivandrum, India.
Hepatitis B virus (HBV) remains a significant global health problem, particularly in India, where its prevalence is gradually decreasing, both in the general population and among healthcare workers. The management of HBV treatment should be individualized based on key factors such as HBV DNA levels, alanine transaminase (ALT) levels, and the presence of comorbid conditions like diabetes mellitus (DM), metabolic dysfunction associated steatotic liver disease (MASLD), pregnancy, cirrhosis, and decompensated cirrhosis. The "treat for all" strategy, although debated, was partially endorsed by the Indian National Association for the Study of the Liver (INASL).
View Article and Find Full Text PDFAccomplishments and challenges in developing improved influenza vaccines: An evaluation of three years of progress toward the milestones of the influenza vaccines research and development roadmap.
Vaccine
August 2025
Center for Infectious Disease Research and Policy, C315 Mayo Memorial Building, MMC 263, 420 Delaware Street, SE, Minneapolis, MN 55455. 612-626-6770, United States of America. Electronic address:
Influenza vaccines that provide more effective immunity to seasonal influenza as well as protection against a broad range of emerging influenza viruses with pandemic potential are needed to reduce the public-health burden of influenza and enhance pandemic preparedness. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was published in 2021 to serve as a strategic planning tool to advance influenza vaccine R&D. Following IVR publication, a 3-year monitoring, evaluation, and adjustment (ME&A) program was implemented to assess progress in meeting the milestones outlined in the IVR.
View Article and Find Full Text PDFAdvances in Understanding Long COVID: Pathophysiological Mechanisms and the Role of Omics Technologies in Biomarker Identification.
Mol Diagn Ther
June 2025
Postgraduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marília, São Paulo, Brazil.
Long coronavirus disease (COVID) is a multisystem condition that affects a significant proportion of individuals following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with persistent symptoms ranging from fatigue and cognitive dysfunction to cardiovascular disorders. It is estimated that 30-60% of infected individuals experience symptoms lasting more than 12 weeks. Despite advances in understanding acute infection, the pathophysiological mechanisms underlying long COVID remain unclear.
View Article and Find Full Text PDFT-cell responses induced by SARS-CoV-2 index-virus nanoparticle protein vaccine to the ancestral and omicron variants 6 months following primary vaccination.
Commun Med (Lond)
June 2025
South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Background: The SARS-CoV-2 index-virus nanoparticle protein vaccine (NVX-CoV2373) induces humoral and cell-mediated immune responses that protect against severe COVID-19, including from SARS-CoV-2 variants. Limited information exists on NVX-CoV2373-induced cell-mediated immune responses to ancestral SARS-CoV-2 and the Omicron variant following a homologous booster (third dose), and on T-cell responses following a booster dose compared to a single dose.
Methods: T-cell responses were investigated in participants from a randomised, placebo-controlled, phase 2A/2B trial of NVX-CoV2373 in South Africa, who had a blinded crossover at 6 months post-enrolment.